Semaglutide vs. tepoxetine: Which has fewer side effects and is better tolerated?

March 3, 2025

Semaglutide (trade name: Vigovi) and telpotide are currently the two most popular GLP-1 receptor agonist weight loss drugs . They can both reduce appetite, delay gastric emptying, and lower blood sugar , thereby helping patients achieve weight management.

However, when choosing a slimming injection, many users not only pay attention to the weight loss effect, but also pay special attention to side effects and tolerance . After all, long-term use of a drug, whether it can be persisted, and whether there will be serious side effects are key factors in determining the success of weight loss.

So, which one has fewer side effects, semaglutide or telpotide? Which one is better tolerated? This article will make a detailed comparison of the types of side effects, incidence, long-term tolerance , etc. to help you find the best choice for you.

1. Semaglutide vs. tepoxetine: comparison of side effects

Side effect category	Semaglutide (Vigovi)	Telportide
Gastrointestinal discomfort (nausea, vomiting)	More serious , affecting the long-term use of some patients	Mild , because GIP can reduce nausea
Diarrhea / constipation	May occur	May occur, but milder
Hypoglycemia (when taken with insulin)	Low	Low
Injection site reactions	slight	slight
Risk of pancreatitis	Low, but needs monitoring	Low, but need to be monitored
Thyroid cancer risk	Potentially risky (contraindicated in patients with MTC and MEN 2 )	Potentially risky (contraindicated in patients with MTC and MEN 2 )

Core conclusions :

Semaglutide has stronger gastrointestinal side effects, and many patients find it difficult to tolerate problems such as nausea and vomiting.
Due to the action of GIP , tepoxetine can reduce GLP-1- related nausea reactions, resulting in lighter gastrointestinal discomfort and better tolerance.
Both have similar risks of other side effects (such as pancreatitis and hypoglycemia), and neither is suitable for people with a history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 ( MEN 2 ).

2. Gastrointestinal side effects: Which is easier to tolerate?

Why do GLP-1 receptor agonists cause gastrointestinal discomfort? GLP-1 drugs act primarily on the brain and digestive system to reduce calorie intake by reducing appetite and delaying stomach emptying , but this process can cause side effects such as nausea, vomiting, bloating, diarrhea or constipation , especially in the early stages of increasing the dose.

Semaglutide vs. telpotide: Gastrointestinal side effects data

• STEP-1 study (semaglutide) : After 68 weeks, 44% of patients experienced nausea, 24% experienced vomiting, and 30% experienced diarrhea .

• SURMOUNT-1 study (tilpoxetine) : After 72 weeks, the incidence of nausea, vomiting and diarrhea with tilpoxetine was 31% , 18% and 21% , respectively , all lower than that with semaglutide.

Why does tebuconazole have fewer gastrointestinal side effects?

• Telpotide additionally activates GIP receptors , which have the effect of reducing nausea and improving gastrointestinal tolerance . Therefore, many patients experience less stomach discomfort and a lower incidence of side effects when taking telpotide.

in conclusion :

• Tipol has milder gastrointestinal side effects and is better tolerated than semaglutide, making it suitable for long-term use.

• If you have experienced severe nausea and vomiting with semaglutide, tebuconazole may be a better choice.

3. Long-term tolerance comparison: Which one is more suitable for long-term use?

Long-term tolerability depends on the following factors:

Will the side effects lessen over time?
Will it affect your daily life and work?
Can it be used for a long time?

drug	Side effect relief time	Long-term compliance (persistence rate)
Semaglutide (Vigovi)	About 8-12 weeks	Some patients stopped taking the drug due to gastrointestinal discomfort
Telportide	About 4-8 weeks	Higher long-term adherence rate and fewer side effects

Research data:

• In the SURMOUNT-1 study, a higher proportion of patients remained on tebuconazole after 72 weeks, primarily due to milder gastrointestinal side effects.

• In the STEP-1 study, some patients were unable to adhere to long-term use of Vigovi due to severe side effects such as nausea and vomiting.

in conclusion :

• Tipol has better long-term tolerability and a lower incidence of side effects, so patients are more likely to adhere to its use.

• If you want to use weight loss injections for a long time, tebuconazole is more adaptable and more suitable for daily life.

4. Conclusion: Which has fewer side effects? Which has better tolerance?

Comparison of Gastrointestinal Side Effects :

• Semaglutide has a higher incidence of nausea, vomiting, and diarrhea , and many patients find it difficult to adhere to the drug for a long time.

• The gastrointestinal side effects of tepoxetine are relatively mild , as the effect of GIP alleviates the nausea and discomfort caused by GLP-1 .